データなし
データなし
Biodexa Pharmaceuticals Price Analysis: Can the 68% Rally Continue?
12 Health Care Stocks Moving In Thursday's Intraday Session
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms...
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (RGBM), the Deadliest Brain Cancer
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
データなし
データなし